Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Number of holders
-
26
-
Total principal
-
308M
-
Principal change
-
-6.43M
-
Total reported value, excl. options
-
$289M
-
Value change
-
-$7.33M
-
Number of buys
-
12
-
Number of sells
-
-8
-
Price
-
$1.09
Significant Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q3 2022
24 filings reported holding 761330AB5 - REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q3 2022.
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 has 26 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $308M of principal
.
Largest 10 bondholders include FRANKLIN RESOURCES INC ($48M of principal), BNP PARIBAS ARBITRAGE, SNC ($41.5M of principal), COWEN AND COMPANY, LLC ($36.6M of principal), LAZARD ASSET MANAGEMENT LLC ($32.6M of principal), AVIVA PLC ($25.3M of principal), Antara Capital LP ($24.2M of principal), Kohlberg Kravis Roberts & Co. L.P. ($21M of principal), UBS OCONNOR LLC ($20M of principal), Voya Investment Management LLC ($15M of principal), and DeepCurrents Investment Group LLC ($10.4M of principal).
This table shows the top 26 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.